A multicenter, open-label, first in human study of a vector expressing and agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors.
NG-641: A T-SIGn vector targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas.
Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW. PLoS ONE 2008; 3 (6):e2409.
Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy and Len W. Seymour
Journal for ImmunoTherapy of Cancer (2018) 6:55
Tzveta D. Pokrovska, Egon J. Jacobus, Rathi Puliyadi, Remko Prevo, Sally Frost, Arthur Dyer, Richard Baugh, Gonzalo Rodriguez-Berriguete, Kerry Fisher, Giovanna Granata, Katharine Herbert, William K. Taverner, Brian R. Champion, Geo S. Higgins, Len W. Seymour,* and Janet Lei-Rossmann
Cancers 2020, 12, 798
William K. Taverner, Egon J. Jacobus, John Christianson, Brian Champion, Adrienne W. Paton, James C. Paton, Weiheng Su, Ryan Cawood, Len W. Seymour, and Janet Lei-Rossmann
Molecular Therapy: Oncolytics Vol. 15 December 2019
Dyer A, Ying D, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, et al. Mol Ther Oncolytics. 2017;4:18-30.
